tbuckley/cabot-search huggingface dataset:
08.05 How do glycans affect immune cells in ra?
Authors: Anoushka K Molhoek, Joyce Lübbers, Juan J Garcia-Vellejo, Sandra J van Vliet, René E.M. Toes, Yvette van Kooyk
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Anti-Citrullinated Protein Antibodies (ACPAs) are specific for Rheumatoid Arthritis (RA) and have been implicated in disease pathogenesis. The fragment antigen-binding domain of ACPA was recently shown to be extensively glycosylated. It is known that glycans play a key role in controlling innate and adaptive immunity, however to date there is limited understanding on the mode of action of glycans in RA. We hypothesise that the glycans on ACPA interact with glycan binding receptors and thus modulate immune responses in RA. Therefore, our aim is to elucidate the glycan effect of ACPA and other glycans on immune cells of RA patients to increase our understanding of RA pathogenesis. <h3>Materials and methods</h3> A whole blood flow assay is used to study glycan interactions with leukocytes. Leukocytes were isolated from blood using Ficoll density centrifugation and lysis of erythrocytes. Cells were incubated for 4 hours with 4 µg/ml glycan at 4°C. Used biotinylated glycans include: sialic acid, Lewis-x, mannose, lactosamine, galactosamine and as a negative control glucitol. Glycan binding and identification of immune cell subsets was assessed with flow cytometry using a whole blood flow antibody panel. <h3>Results</h3> A whole blood flow assay of four healthy donors showed consistent high binding of mannose to B-cells. Interestingly, no binding of mannose was observed to other immune cells indicating that mannose binds specifically to B cells. At this concentration there was no binding of other glycans to leukocytes. When there is a difference in glycan binding between healthy and RA patients CyTOF3-Helios mass cytometer will be used to have a more in-depth analyse of the interacting leukocyte cell subsets. <h3>Conclusion</h3> This study examines the glycan-binding capacity of leukocytes in healthy donors and RA patients via the whole blood flow assay. Our preliminary data indicates specific binding of mannose to B cells. This is an important finding because B cells play a key role in the pathogenesis of RA, as they produce ACPA and are very efficient in antigen presentation. Further studies on glycan binding to other key immune cells in RA may aid in elucidating their role in the pathogenesis of RA.
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy
Authors: Elisabeth Pérez-Ruiz, Iñaki Etxeberria, Maria E. Rodriguez-Ruiz, Ignacio Melero
Journal: Clinical Cancer Research (2017)

T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
NK/T non-Hodgkin’s lymphoma xenografts as a model for therapeutic intervention
Authors: Ghee Chong Koo, Mohammed Sham Mohammed Saleh, Hung Huynh, Jacqueline Siok Gek Hwang, Soon-Thye Lim, Miriam Tao, Tsung-Wen Chong, Leonard Hwan Cheong Tan, Susan Li Er Loong
Journal: Clinical Cancer Research (2007)

B28  NK/T cell non-Hodgkin’s lymphomas (NHL) occur more frequently in Asia and areas of South and Central America but are rare in United States and other Western populations. Disseminated NK/T NHL are mostly incurable and respond poorly to conventional, anthracycline-base regimens. We have established an EBV positive NK lymphoma xenograft (NK-S1) in SCID mice from the testicular metastasis of a patient with nasal-type NK lymphoma. NK-S1 still retained the same immunophenotypic features as the original tumor, and it was shown to be positive for cytoplasmic CD3, TIA-1, granzyme B and EBER. Furthermore, we have used this xenograft as a model for drug testing and showed previously that doxorubicin had no effect on the growth of subcutaneous NK-S1 xenografts. In this study, we found that treatment with gemcitabine caused complete remission of NK-S1 tumors at 60mg/kg by intraperitoneal injection on either the q3d x2 or q7d x4 schedules. Regression of tumors was visible at 24 h after treatment. Although weight loss was observed in the gemcitabine treated mice, the regimens used did not lead to other severe side effects or death. In conclusion, NK-S1 xenograft model can serve as a useful tool to provide representative in vivo platform for rational preclinical drug testing.
Letter by Niccoli et al Regarding Article, “Intracoronary Versus Intravenous Administration of Abciximab in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration: The Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial”
Authors: Giampaolo Niccoli, Nicola Cosentino, Filippo Crea
Journal: Circulation (2011)
非常に効率的な細胞内蛋白質送達のためのフィブロイン粒子支持カチオン性脂質層【Powered by NICT】
Authors: Kim Woo-Jin, Kim Bong-Soo, Cho Young-Dan, Yoon Won-Joon, Baek Jeong-Hwa, Woo Kyung-Mi, Ryoo Hyun-Mo
Journal: Biomaterials (2017)
Fibroblasts and the extracellular matrix in right ventricular disease
Authors: Nikolaos G. Frangogiannis
Journal: Cardiovascular Research (2017)

Right ventricular failure predicts adverse outcome in patients with pulmonary hypertension (PH), and in subjects with left ventricular heart failure and is associated with interstitial fibrosis. This review manuscript discusses the cellular effectors and molecular mechanisms implicated in right ventricular fibrosis. The right ventricular interstitium contains vascular cells, fibroblasts, and immune cells, enmeshed in a collagen-based matrix. Right ventricular pressure overload in PH is associated with the expansion of the fibroblast population, myofibroblast activation, and secretion of extracellular matrix proteins. Mechanosensitive transduction of adrenergic signalling and stimulation of the renin-angiotensin-aldosterone cascade trigger the activation of right ventricular fibroblasts. Inflammatory cytokines and chemokines may contribute to expansion and activation of macrophages that may serve as a source of fibrogenic growth factors, such as transforming growth factor (TGF)-β. Endothelin-1, TGF-βs, and matricellular proteins co-operate to activate cardiac myofibroblasts, and promote synthesis of matrix proteins. In comparison with the left ventricle, the RV tolerates well volume overload and ischemia; whether the right ventricular interstitial cells and matrix are implicated in these favourable responses remains unknown. Expansion of fibroblasts and extracellular matrix protein deposition are prominent features of arrhythmogenic right ventricular cardiomyopathies and may be implicated in the pathogenesis of arrhythmic events. Prevailing conceptual paradigms on right ventricular remodelling are based on extrapolation of findings in models of left ventricular injury. Considering the unique embryologic, morphological, and physiologic properties of the RV and the clinical significance of right ventricular failure, there is a need further to dissect RV-specific mechanisms of fibrosis and interstitial remodelling.
Consultant is suspended for nine months for risking patient safety
Authors: Clare Dyer
Journal: BMJ (2017)

A consultant haematologist who belittled colleagues, held out the promise of a cure to a patient with advanced lymphoma, and entered a patient’s home to leave a note has been suspended for nine months by a fitness to practise tribunal that called her conduct a potential risk to patients.

Finella Brito-Babapulle, 63, inappropriately contacted patients within a few days of finishing her locum job at St Mary’s Hospital on the Isle of Wight, in one case offering “false hope” of a cure to an 84 year old patient with lymphoma.

Panel chair Janet Nicholls told Brito-Babapulle that in her testimony she had attempted “to discredit the tribunal’s …
Intra-articular Melanoma Metastasis in the Ankle Joint
Authors: Jennifer Murphy, Ian Brennan, Ciaran Johnston
Journal: Clinical Nuclear Medicine (2017)

Intra-articular melanoma metastases are rare. We present a case of a 65-year-old woman with metastatic melanoma in the right ankle joint. 18F-FDG PET/CT was performed from the vertex to the toes, which demonstrated FDG-avid inguinal lymphadenopathy and an intensely FDG-avid soft tissue mass adjacent to the neck of the talus within the right ankle joint. The intra-articular mass was subsequently resected and histologically confirmed as metastatic melanoma. This case emphasizes the value of the contemporaneous CT in these studies for accurate anatomical localization in diagnostically challenging clinical scenarios.
08.17 The paradoxical effects of tnf-α on osteoblastogenesis
Authors: Seong-Ryul Kwon, Won Park, Kyong-Hee Jung, Mie-Jin Lim, Min-Jeong Son, Byung-Heon Choi, Shin-Goo Park
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objective</h3> The full effect of anti-TNF therapy on new bone formation is still in debate in spondylitis fields. We sought to obtain circulating osteoblast-lineage cells in peripheral blood from ankylosing spondylitis (AS) patients and healthy control subjects, and to evaluate the effect of TNF-α on osteoblastogenesis in patients with AS before and after infliximab therapy. <h3>Methods</h3> Sixteen male patients with AS slated for infliximab therapy and 19 controls were recruited. We cultured osteoblast-lineage cells from peripheral blood and measured the optical density of their alizarin red S staining. We also measured serum P1NP (procollagen type 1 N-terminal propeptide) as an early osteoblast differentiation marker, osteocalcin as a late osteoblast differentiation marker, and inflammatory markers. <h3>Results</h3> There were significantly more circulating osteoblast-lineage cells in patients than in controls. The number of circulating osteoblast-lineage cells and optical density of Alizarin S staining decreased 14 weeks after infliximab therapy (p=0.028); serum level of P1NP decreased, but that of osteocalcin increased (p=0.002 and 0.007 respectively). <h3>Conclusion</h3> Our data reveals first, TNF-α stimulates osteoblastogenesis before infliximab therapy in patients with AS; second, infliximab therapy resolves early inflammation, but allows mature osteoblast differentiation in late inflammation. The culture of osteoblast-lineage cells in peripheral blood may be a candidate for a new modality with which study spondylitis and other autoimmune diseases. <h3>Funding</h3> This study is supported by grant from the National Research Foundation of Korea (NRF-2014R1A1A2058007) to Dr. S-R Kwon
緩和な温熱療法増強された化学療法のための三刺激応答性生分解性セラノスティックス【Powered by NICT】
Authors: Lu Nan, Huang Peng, Fan Wenpei, Wang Zhantong, Liu Yijing, Wang Sheng, Zhang Guofeng, Hu Junkai, Liu Wenfei, Niu Gang, D Leapman Richard, Lu Guangming, Chen Xiaoyuan
Journal: Biomaterials (2017)
Carbon Nanomaterials in Biological Studies and Biomedicine
Authors: Nagappa L. Teradal, Raz Jelinek
Journal: Advanced Healthcare Materials (2017)

The "carbon nano-world" has made over the past few decades huge contributions in diverse scientific disciplines and technological advances. While dramatic advances have been widely publicized in using carbon nanomaterials such as fullerenes, carbon nanotubes, and graphene in materials sciences, nano-electronics, and photonics, their contributions to biology and biomedicine have been noteworthy as well. This Review focuses on the use of carbon nanotubes (CNTs), graphene, and carbon quantum dots [encompassing graphene quantum dots (GQDs) and carbon dots (C-dots)] in biologically oriented materials and applications. Examples of these remarkable nanomaterials in bio-sensing, cell- and tissue-imaging, regenerative medicine, and other applications are presented and discussed, emphasizing the significance of their unique properties and their future potential.
<i>Notes from the Field</i>: Zika Virus-Associated Neonatal Birth Defects Surveillance — Texas, January 2016–July 2017
Authors: Noemi Borsay Hall, Kelly Broussard, Nicole Evert, Mark Canfield
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

On November 28, 2016, the Texas Department of State Health Services (Texas DSHS) reported its first confirmed case of local mosquitoborne Zika virus transmission in the city of Brownsville, located in south Texas along the U.S.-Mexico border. Zika virus infection during pregnancy has been linked to adverse congenital outcomes including microcephaly, neural tube defects, early brain malformations, structural eye abnormalities, congenital deafness, and limb contractures (1). On January 1, 2016, Texas DSHS established enhanced surveillance to identify women with laboratory evidence of possible Zika virus infection during pregnancy and suspected cases of Zika virus-associated birth defects among completed pregnancies.
Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome
Authors: Giusi Prencipe, Ivan Caiello, Antonia Pascarella, Alexei A. Grom, Claudia Bracaglia, Laurence Chatel, Walter G. Ferlin, Emiliano Marasco, Raffaele Strippoli, Cristina de Min, Fabrizio De Benedetti
Journal: Journal of Allergy and Clinical Immunology (2017)
“Poker” schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study
Authors: A. Santomaggio, E. Ricevuto, K. Cannita, G. Bruera, M. Tudini, P. Lanfiuti Baldi, M. Mancini, G. Porzio, P. Marchetti, C. Ficorella
Journal: Journal of Clinical Oncology (2009)

4125 Background: Triplet combinations associating antimetabolites with irinotecan (CPT-11) and/or oxaliplatin (OHP) and/or bevacizumab (BEV) show increased activity in same phase III studies vs doublets, with objective responses (OR) between 40% and 60%. Thus we evaluated in a phase II study the addition of BEV to the triplet combination CPT-11/OHP/5-fluorouracil (5-FU) as first line chemotherapy in metastatic colorectal carcinoma (MCC). Methods: Main inclusion criteria: histologically diagnosis of colorectal cancer (CRC) with measurable disease; age 18–75 yrs; adequate bone marrow reserve and renal and hepatic function; no cardiac diseases; no uncontrolled hypertension; no thromboembolic diseases or coagulopathy, no preexisting bleeding diatheses. Treatment schedule: weekly 5-FU 12-h timed-flat-infusion (from 10:00 pm to 10:00 am) 900 mg/m 2 /d 1–2, 8–9, 15–16 and 22- 23; CPT-11 160 mg/m 2 plus BEV 5 mg/kg days 1 and 15; OHP 80 mg/m 2 days 8 and 22, every 4 weeks. A Simon two-stage optimal design was planned: power 80%, error probability α 5%, error probability β 20%, P 0 50%, P 1 70%, sample size 43 pts (I stage 8/15 OR; II stage 26/43 OR). Primary endpoint: OR. Secondary endpoints: time to progression (TTP), overall survival (OS), toxicity and quality of life. Results: Forty-eight pts were enrolled. Median number of cycles per patient was 5 (range 1–9). In the expected 43 pts assessable intent-to-treat (ITT), OR were 84% (α0.05, CI +12): 2 complete and 34 partial responses. In the overall 48 pts, 46 were assessable ITT: OR 80% (α0.05, CI +12), 2 complete and 35 partial responses, 4 stable disease and 5 progression. Median TTP was 12 months (2+-33+), median OS was 25 months (2+-34+), with a median follow-up of 12 months (2–34). Cumulative G3–4 toxicities by pts were: diarrhea 27%, mucositis 6%, hypertension 2%, hypertransaminasemy 2%, neutropenia 10%. No toxic deaths have occurred. Received-DI: CPT-11 84% of projected-DI, OHP 82%, 5-FU 85%, BEV 84%, per pt respectively. 17 pts (35%) had only liver metastasis and R0 resection was performed in 3 pts (18%). Conclusions: “Poker” combination with FIR-B/FOX schedule shows higher activity than triplet combinations. Thus it may be considered as the most active first line treatment of MCC. No significant financial relationships to disclose.
Hematopoietic Stem Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplant Unit in Bangladesh and Initial Outcomes
Authors: Albert C. Yeh, Mohiuddin Ahmed Khan, Sabrina Khan, Jason Harlow, Akhil Biswas, Mafruha Akter, Jannatul Ferdous, Tasneem Ara, Manirul Islam, Anne-Marie Barron, Jenna Moran, Mark Brezina, Anup Saha, Salma Afrose, Christopher P. Stowell, Frederic Preffer, David Bangsberg, Annekathryn Goodman, Eyal C. Attar, Steven L. McAfee, Thomas R. Spitzer, Bimalangshu R. Dey
Journal: Blood (2016)
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia
Authors: Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Weili Sun, Meina Liang, Jie Yang, Robert J. Kreitman, Mark C. Lanasa, Ira Pastan
Journal: Blood (2017)
OP0062 The fully human anti-tnf antibody adalimumab (d2e7) in combination with methotrexate (mtx) in the treatment of active rheumatoid arthritis: results of a 2-year study
Authors: FC Breedveld, CF Allaart, R Rau, G Herborn, S Wassenberg, EJ Kroot, PL Van Riel, LB Van de Putte, C Böger, M Schattenkirchner, J Kempeni, K Beck, H Kupper
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To evaluate the long-term efficacy and safety of a combination of methotrexate (MTX) with the fully human anti-TNF antibody adalimumab (D2E7) in patients with active rheumatoid arthritis (RA). <h3>Methods</h3> 54 patients, who were partial responders to standard doses of MTX (mean 16 mg/week), were included in this randomised double blind, placebo-controlled study (DE010). Initially, patients were randomised into three treatment arms of 18 patients each and then injected double blind (first and second injection) with either 1 mg/kg adalimumab i.v., 1 mg/kg adalimumab s.c., or placebo (double dummy). Thereafter, all patients received open-label s.c. injections of 1 mg/kg adalimumab. The frequency of administration (every other week up to every other month) depended on the individual response to treatment. <h3>Results</h3> The overall efficacy results for the open label period of 24 months are summarised in the Table 1 below. Adverse events were well matched between both adalimumab treatment arms and placebo during the initial double blind study period. A total of 44 patients (81%) were able to complete the 2-year study period. Reasons for drop out were adverse events (6 pts), lack of efficacy (2 pts), death (1 pt, myocardial infarction), and protocol violation (1 pt). <h3>Conclusion</h3> Repeated subcutaneous injections of 1 mg/kg adalimumab (D2E7) over a period of two years showed sustained efficacy and were well tolerated when given in combination with stable standard doses of MTX to patients with active RA.
重度の出血性ショックにおける急性肝損傷を軽減するカルボキシフラーレンナノ粒子【Powered by NICT】
Authors: Chen Gan, Song Xiang, Wang Bo, You Guoxing, Zhao Jingxiang, Xia Sha, Zhang Yuhua, Zhao Lian, Zhou Hong
Journal: Biomaterials (2017)
THE EFFICACY OF FIFA 11+OVER A 6-YEAR PERIOD, IN ADOLESCENT FOOTBALL PLAYERS
Authors: Yasuaki Saho, Haruyasu Kato, Nakahori Chikako, Hiroshi Ikeda, Toru Fukubayashi
Journal: British Journal of Sports Medicine (2017)

Background FIFA 11+ program has been shown to reduce the risk of injury in football players, but it has not been evaluated in adolescent Japanese players. Objective To investigate the effects of FIFA 11+on the risk of injury in adolescent Japanese football players. Design Cohort study. Setting Six male and 4 female Japanese Under-18 (age: 16–18 yr.) and Under-15 (age: 13–15 yr.) football teams were followed for six seasons (from 2010 to 2015). The 2010 season was considered as the control season, with the players practicing their usual warm-up techniques. Throughout the seasons from 2011 to 2015, the players exclusively performed FIFA 11+; these 5 seasons were considered the intervention seasons. Participants A total of 2,344 athletes (1,815 male, 529 female; age: 12–18 yr.). Interventions FIFA 11+program was conducted at least twice per week, throughout the intervention seasons. Main Outcome Measurements For each of the three categories: football [matches+trainings], matches, and trainings, the injury rates were reported as the number of injuries per 1000 player-hours (1000PH). Results In males, the injury rate during football, the matches, and the trainings were 4.0, 8.9, and 3.4 in the control season, and 2.4, 6.9, and 1.8 in intervention seasons (mean values from 2011 to 2015), respectively. In females, the injury rates during football, the matches, and the trainings were 2.7, 2.2, and 7.5 in the control season, and 3.1, 2.6, and 8.9 in intervention seasons (mean values from 2011 to 2015).The injury rates were reduced significantly in the intervention seasons, compared with the control season in males, but not in females. Non-contact injuries were significantly reduced in both genders. Conclusions FIFA 11+program reduced the risk of injury in adolescent Japanese male football players, and reduced non-contact injuries in adolescent Japanese female football players.
Guidelines of care for the management of psoriasis and psoriatic arthritis
Authors: Alan Menter, Alice Gottlieb, Steven R. Feldman, Abby S. Van Voorhees, Craig L. Leonardi, Kenneth B. Gordon, Mark Lebwohl, John Y.M. Koo, Craig A. Elmets, Neil J. Korman, Karl R. Beutner, Reva Bhushan
Journal: Journal of the American Academy of Dermatology (2008)